Skip to content

A double blind placebo controlled discontinuation of citalopram in adolescents with major depression

A double blind placebo controlled discontinuation of citalopram in adolescents with major depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN42386710
Enrollment
214
Registered
2005-09-05
Start date
2002-04-01
Completion date
Unknown
Last updated
2019-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder Mental and Behavioural Disorders Depression

Interventions

Citalopram versus placebo

Sponsors

Sunnybrook and Women's College Health Sciences Centre (Canada)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Major depression determined from both clinical interview and the Kiddie-Sads-Present and Lifetime Version (K-SADS-PL) 2. Subjects who score greater than 16 on the first 17 items of the 29 item Hamilton Rating Scale for Depression - Seasonal Affective Disorder (HRSD-SAD) version or those who score greater than 12 on the 17 item of the 29 items HRSD and greater than 7 on the atypical items 3. Age 13 to 18 years 4. Both sexes; females who have reached menarche and are sexually active will be advised to take adequate birth control (BCP or two barrier methods) 5. Outpatient at the time of initiation of the continuation phase 6. Ability to give informed consent

Exclusion criteria

Exclusion criteria: 1. Past or currently hypomanic or manic episode 2. Currently meets criteria for conduct disorder 3. Current psychotic symptoms 4. Substance dependence in the last 3 months 5. Significant medical condition that would contra-indicate the use of antidepressant agents 6. Pregnancy 7. Past treatment with citalopram for major depression

Design outcomes

Primary

MeasureTime frame
Relapse = the subject meets criteria for an episode of major depression.

Secondary

MeasureTime frame
A CGI-I score of -2 or -3 (on a 7 point scale) or more, reflecting at least 'moderate worsening' of the clinical condition.

Countries

Canada

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026